Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 20/20 | 0.73 |
| ▸ | FNTB | P49356 | 20/20 | 0.73 |
| ▸ | HRAS | P01112 | 1/20 | 0.59 |
| ▸ | KRAS | P01116 | 1/20 | 0.59 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3499278 | 1.00 | FNTA (0.73) | FNTAFNTBHRASKRASPGGT1B | |
| SCHEMBL3500829 | 0.98 | FNTA (0.71) | FNTAFNTBHRASKRASPGGT1B | |
| SCHEMBL3502128 | 0.98 | FNTA (0.71) | FNTAFNTBHRASKRASPGGT1B | |
| SCHEMBL3499925 | 0.98 | FNTA (0.70) | FNTAFNTBHRASKRASPGGT1B | |
| SCHEMBL3502451 | 0.96 | FNTA (0.68) | FNTAFNTBHRASKRASPGGT1B | |
| SCHEMBL3502449 | 0.96 | FNTA (0.68) | FNTAFNTBHRASKRASPGGT1B | |
| SCHEMBL3501571 | 0.95 | FNTA (0.68) | FNTAFNTBHRASKRASPGGT1B | |
| SCHEMBL3500003 | 0.95 | FNTA (0.68) | FNTAFNTBHRASKRASPGGT1B | |
| SCHEMBL3500485 | 0.95 | FNTA (0.68) | FNTAFNTBHRASKRASPGGT1B | |
| SCHEMBL3501575 | 0.95 | FNTA (0.68) | FNTAFNTBHRASKRASPGGT1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7074921-B2 | Process for the preparation of 3,7-disubstituted-2,3,4,5-tetrahydro-1H-1,4-benzodiazepine compounds | BRISTOL MYERS SQUIBB COMPANY (US) | 2006-07-11 | — | — | US | claimed |
| US-20050272722-A1 | Methods for the treatment of synucleinopathies | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2005-12-08 | — | — | US | claimed |
| US-20030162965-A1 | Process for the preparation of 3,7-disubstituted-2,3,4,5-tetrahydro-1H-1,4-benzodiazepine compounds | BRISTOL-MYERS SQUIBB COMPANY | 2003-08-28 | — | — | US | claimed |
| US-6537988-B2 | Imidazole-1h-1,4-benzodiazepine derivatives along with antiproliferative cytotoxic and cytostatic agents | BRISTOL-MYERS SQUIBB COMPANY | 2003-03-25 | — | — | US | claimed |
| US-6455523-B1 | ADMINISTERING 1,4-BENZODIAZEPINE DERIVATIVE AS ANTITUMOR OR ANTICARCINOGENIC AGENT | BRISTOL-MYERS SQUIBB COMPANY | 2002-09-24 | — | — | US | claimed |
| US-20020002162-A1 | Synergistic methods and compositions for treating cancer | BRISTOL-MYERS SQUIBB COMPANY | 2002-01-03 | — | — | US | claimed |
| US-20110294794-A1 | TREATMENT OF PROTEINOPATHIES USING A FARNESYL TRANSFERASE INHIBITOR | LINK MEDICINE CORPORATION (US) | 2011-12-01 | — | — | US | disclosed |
| WO-2010057028-A9 | TREATMENT OF PROTEINOPATHIES USING A FARNESYL TRANSFERASE INHIBITOR | LINK MEDICINE CORPORATION (US) | 2010-09-02 | — | — | WO | disclosed |
| US-20100184803-A1 | Treatment of Lysosomal Storage Diseases | LINK MEDICINE CORPORATION (MA) | 2010-07-22 | — | — | US | disclosed |
| WO-2010057028-A2 | TREATMENT OF PROTEINOPATHIES USING A FARNESYL TRANSFERASE INHIBITOR | LINK MEDICINE CORPORATION (US) | 2010-05-20 | — | — | WO | disclosed |
| EP-2155197-A2 | TREATMENT OF LYSOSOMAL STORAGE DISEASES | Link Medicine Corporation (US) | 2010-02-24 | — | — | EP | disclosed |
| WO-2008112525-A2 | TREATMENT OF LYSOSOMAL STORAGE DISEASES | LINK MEDICINE CORPORATION (US) | 2008-09-18 | — | — | WO | disclosed |
| US-20070293539-A1 | Methods for the treatment of synucleinopathies | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2007-12-20 | — | — | US | disclosed |
| US-20030162965-A1 | Process for the preparation of 3,7-disubstituted-2,3,4,5-tetrahydro-1H-1,4-benzodiazepine compounds | BRISTOL-MYERS SQUIBB COMPANY | 2003-08-28 | — | — | US | disclosed |
| WO-2003041658-A2 | PROCESS FOR THE PREPARATION OF 3,7-DISUBSTITUTED-2,3,4,5- TETRAHYDRO-1H-1,4-BENZODIAZEPINE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-05-22 | — | — | WO | disclosed |
| US-6537988-B2 | Imidazole-1h-1,4-benzodiazepine derivatives along with antiproliferative cytotoxic and cytostatic agents | BRISTOL-MYERS SQUIBB COMPANY | 2003-03-25 | — | — | US | disclosed |
| US-20020169313-A1 | Production of tertiary amines by reductive amination | BRISTOL-MYERS SQUIBB COMPANY | 2002-11-14 | — | — | US | disclosed |
| US-6455523-B1 | ADMINISTERING 1,4-BENZODIAZEPINE DERIVATIVE AS ANTITUMOR OR ANTICARCINOGENIC AGENT | BRISTOL-MYERS SQUIBB COMPANY | 2002-09-24 | — | — | US | disclosed |
| US-20020002162-A1 | Synergistic methods and compositions for treating cancer | BRISTOL-MYERS SQUIBB COMPANY | 2002-01-03 | — | — | US | disclosed |
| US-6011029-A | BENZODIAZEPINE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050272722-A1 | Methods for the treatment of synucleinopathies | SNCA, PARK7, NLN | FNTA 24/4885FNTB 49/4885HRAS 588/4885 |
| US-20020169313-A1 | Production of tertiary amines by reductive amination | FNTB, ACAT2, SOAT2 | FNTA 7/4885FNTB 1/4885HRAS 2139/4885 |
| US-20100184803-A1 | Treatment of Lysosomal Storage Diseases | GAA, GBA1, MAN2B1 | FNTA 19/4885FNTB 24/4885HRAS 2718/4885 |
| US-20070293539-A1 | Methods for the treatment of synucleinopathies | SNCA, PARK7, NLN | FNTA 24/4885FNTB 49/4885HRAS 588/4885 |
| US-20030162965-A1 | Process for the preparation of 3,7-disubstituted-2,3,4,5-tetrahydro-1H-1,4-benzodiazepine compounds | GABRA4, GABRA3, GABRA6 | FNTA 43/4885FNTB 27/4885HRAS 3246/4885 |
| US-20110294794-A1 | TREATMENT OF PROTEINOPATHIES USING A FARNESYL TRANSFERASE INHIBITOR | FNTA, FNTB, BDNF | FNTA 1/4885FNTB 2/4885HRAS 13/4885 |
| US-20020002162-A1 | Synergistic methods and compositions for treating cancer | ABCB11, TP53, SLC10A1 | FNTA 1166/4885FNTB 1798/4885HRAS 572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.